Alvin Kingcade
Physician Assistant · Philadelphia, PANPI 1881711125
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Gilead at 49.7% of the total. 2025 is the largest year on record at $21,969, 5.7 times the $3,883 reported in 2021. Among physician assistant clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 525 payments — averaging $129.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$34K
- Viiv Healthcare Company$14K
- Janssen Scientific Affairs, LLC$14K
- AbbVie$1K
- AstraZeneca$1K
- Janssen Products, LP$764
- plus $3K from 18 others
Across 15 payments — averaging $2168.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viiv Healthcare Company$33K
What the payments were for
- Consulting fees$10,09515%
- Speaking & faculty fees$33,40049%
- Travel & lodging$8,13412%
- Food & beverage$16,20824%
- Education$1790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 157 | $33,802 |
| Viiv Healthcare Company | 209 | $14,437 |
| Janssen Scientific Affairs, LLC | 25 | $13,839 |
| AbbVie | 21 | $1,143 |
| AstraZeneca | 12 | $1,139 |
| Janssen Products, LP | 3 | $764 |
| Merck | 27 | $577 |
| Johnson & Johnson | 24 | $556 |
| Galderma Laboratories, L.p. | 3 | $345 |
| Theratechnologies Inc. | 17 | $284 |
| Lilly USA, LLC | 5 | $256 |
| Merz North America, Inc. | 1 | $169 |
| Pfizer | 1 | $129 |
| Teva Pharmaceuticals USA, Inc. | 2 | $119 |
| EMD Serono, Inc. | 1 | $109 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $68 |
| Novo Nordisk | 3 | $64 |
| Hologic Sales And Service, LLC | 3 | $56 |
| Alkermes, Inc. | 2 | $38 |
| Bayer | 2 | $38 |
| GSK | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Novartis | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$68,016 in reported general payments places this provider in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 206 | $814,521 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 54 | $203,458 |
| CabenuvaCabotegravir/Rilpivirine | 30 | $179,102 |
| DovatoDolutegravir Sodium/Lamivudine | 59 | $172,875 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 40 | $142,619 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 31 | $136,972 |
| TivicayDolutegravir Sodium | 52 | $117,946 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 27 | $115,763 |
| DescovyEmtricitabine/Tenofov Alafenam | 46 | $96,203 |
| JulucaDolutegravir/Rilpivirine | 25 | $83,825 |
| OzempicSemaglutide | 78 | $72,843 |
| PrezcobixDarunavir/Cobicistat | 28 | $66,825 |
| JardianceEmpagliflozin | 52 | $32,170 |
| PrezistaDarunavir | 12 | $28,225 |
| EvotazAtazanavir Sulfate/Cobicistat | 15 | $23,692 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $33,802 | $1,026,488279 claims |
| Viiv Healthcare CompanyCabenuva, Dovato, Triumeq, Tivicay, Juluca | $14,437 | $696,368206 claims |
| Janssen Products, LPSymtuza | $764 | $136,97231 claims |
| Novo NordiskOzempic, Rybelsus | $64 | $84,87289 claims |
| Johnson & JohnsonPrezcobix | $556 | $66,82528 claims |
| Janssen Scientific Affairs, LLCPrezista | $13,839 | $28,22512 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $24 | $23,51844 claims |
| Lilly USA, LLCTrulicity | $256 | $19,51417 claims |
| PfizerEliquis | $129 | $19,36132 claims |
| MerckJanuvia | $577 | $6,57412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.
Other physician assistant in Philadelphia
- Melissa FerrariPhiladelphia$223K
- Trevor BonneyPhiladelphia$44K
- Ashwin GuptaPhiladelphia$33K
- Christopher EsworthyPhiladelphia$31K
- Carolyn ZawislakPhiladelphia$29K
- Kristen JonesPhiladelphia$22K
- Simone HoldenPhiladelphia$17K
- Erin CrownState College$1.2M
- Tricia BootsCranberry Twp$313K
- Jason OberdickWexford$206K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.